Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | GLS | O94925 | 4/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL103235 | 0.84 | ALDH1A1 (0.54) | ALDH1A1GAAL3MBTL1KMT2ASMN1; SMN2 | |
| SCHEMBL9539620 | 0.84 | ALDH1A1 (0.54) | ALDH1A1GAAL3MBTL1KMT2ASMN1; SMN2 | |
| SCHEMBL155984 | 0.84 | ALDH1A1 (0.54) | ALDH1A1GAAL3MBTL1KMT2ASMN1; SMN2 | |
| SCHEMBL104518 | 0.84 | ALDH1A1 (0.54) | ALDH1A1GAAL3MBTL1KMT2ASMN1; SMN2 | |
| SCHEMBL3156773 | 0.83 | ALDH1A1 (0.53) | ALDH1A1GAAL3MBTL1KMT2ASMN1; SMN2 | |
| Methane SCHEMBL9122539 | 0.83 | ALDH1A1 (0.53) | ALDH1A1GAAL3MBTL1KMT2ASMN1; SMN2 | |
| SCHEMBL8917738 | 0.83 | ALDH1A1 (0.53) | ALDH1A1GAAL3MBTL1KMT2ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL6178991 | 0.83 | ALDH1A1 (0.53) | ALDH1A1GAAL3MBTL1KMT2ASMN1; SMN2 | |
| Ammonia Solution, Strong SCHEMBL38660904 | 0.83 | ALDH1A1 (0.53) | ALDH1A1GAAL3MBTL1KMT2ASMN1; SMN2 | |
| SCHEMBL15116487 | 0.83 | ALDH1A1 (0.53) | ALDH1A1GAAL3MBTL1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124744-B2 | Macrolide derivatives | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-02-28 | — | — | US | claimed |
| EP-2077271-A1 | MACROLIDE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2009-07-08 | — | — | EP | claimed |
| US-20090076253-A1 | MACROLIDE DERIVATIVES | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2009-03-19 | — | — | US | claimed |
| EP-1740522-A2 | BISPHENYL COMPOUNDS USEFUL AS VITAMIN D SB 3 /SB RECEPTOR AGONISTS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-01-10 | — | — | EP | claimed |
| WO-2005087700-A2 | BISPHENYL COMPOUNDS USEFUL AS VITAMIN D3 RECEPTOR AGONISTS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2005-09-22 | — | — | WO | claimed |
| US-8124744-B2 | Macrolide derivatives | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-02-28 | — | — | US | disclosed |
| EP-2077271-A1 | MACROLIDE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2009-07-08 | — | — | EP | disclosed |
| US-20090076253-A1 | MACROLIDE DERIVATIVES | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2009-03-19 | — | — | US | disclosed |
| EP-1740522-A2 | BISPHENYL COMPOUNDS USEFUL AS VITAMIN D SB 3 /SB RECEPTOR AGONISTS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-01-10 | — | — | EP | disclosed |
| WO-2005087700-A2 | BISPHENYL COMPOUNDS USEFUL AS VITAMIN D3 RECEPTOR AGONISTS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2005-09-22 | — | — | WO | disclosed |
| EP-1329160-A2 | 4-ACYLAMINOPYRAZOLE DERIVATIVES | Sankyo Company, Limited (JP) | 2003-07-23 | — | — | EP | disclosed |
| WO-2000012492-A1 | BENZOXAZINE DERIVATIVES | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2000-03-09 | — | — | WO | disclosed |
| US-5670497-A | RETROVIRAL PROTEASE INHIBITORS | CIBA-GEIGY CORPORATION (US) | 1997-09-23 | — | — | US | disclosed |
| EP-0708760-A1 | CYCLIC HYDRAZINE COMPOUNDS | Novartis AG (CH) | 1996-05-01 | — | — | EP | disclosed |
| WO-1995002582-A1 | CYCLIC HYDRAZINE COMPOUNDS | CIBA-GEIGY AG (CH) | 1995-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076253-A1 | MACROLIDE DERIVATIVES | MMP9, MMP2, MMP11 | ALDH1A1 1697/4885GAA 1402/4885L3MBTL1 4428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.